Article
Oncology
Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph Stoll, Andrea P. Moy, Stephen W. Dusza, Allison Gordon, Elena C. Haliasos, Yelena Janjigian, Lukas Kraehenbuehl, Elizabeth A. Quigley, Paul Chapman, Mario E. Lacouture, Alina Markova
Summary: Immune checkpoint inhibitors (ICI) can effectively target cancer cells, but they may also cause immune-related cutaneous adverse events (ircAEs) in a significant number of patients. This study examined the use of dupilumab for treating ICI-associated ircAEs and found that 87% of patients responded to the treatment, with 44.1% achieving complete resolution of the adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Medicine, General & Internal
Hiroki Hashimoto, Takamichi Ito, Toshio Ichiki, Yuichi Yamada, Yoshinao Oda, Masutaka Furue
Summary: This study retrospectively reviewed 51 patients with cutaneous immune-related adverse events (irAEs) following ICI therapy, showing maculopapular rash as the most common eruption with onset typically within a month. Most rashes improved with appropriate treatment and/or interruption of ICIs.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Chemistry, Medicinal
Stephanie L. Gu, Tara Maier, Andrea P. Moy, Stephen Dusza, David M. Faleck, Neil J. Shah, Mario E. Lacouture
Summary: This study reports the use of ustekinumab as a therapeutic option for patients with immune-related cutaneous adverse events (ircAEs). The results show that ustekinumab showed benefits in a subset of patients and no safety signals were identified. However, further research is needed to confirm these findings.
Article
Endocrinology & Metabolism
Christopher A. Muir, Roderick J. Clifton-Bligh, Georgina Long, Richard A. Scolyer, Serigne N. Lo, Matteo S. Carlino, Venessa H. M. Tsang, Alexander M. Menzies
Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with different subtypes of thyroid immune-related adverse events having unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer progression free survival and overall survival, while hypothyroidism showed no association with cancer outcomes. Multiple distinct phenotypes of thyroid irAEs suggest potentially different etiologies for thyrotoxicosis and hypothyroidism.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Christopher A. Muir, Roderick J. Clifton-Bligh, Georgina V. Long, Richard A. Scolyer, Serigne N. Lo, Matteo S. Carlino, Venessa H. M. Tsang, Alexander M. Menzies
Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with distinct phenotypes of thyroid irAEs showing unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer survival outcomes, while no association was found between hypothyroidism and cancer outcomes.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Oncology
Rafaela Kramer, Anne Zaremba, Alvaro Moreira, Selma Ugurel, Douglas B. Johnson, Jessica C. Hassel, Martin Salzmann, Anja Gesierich, Alison Weppler, Lavinia Spain, Carmen Loquai, Milena Dudda, Claudia Pfoehler, Adriana Hepner, Georgina Long, Alexander M. Menzies, Matteo S. Carlino, Michael M. Sachse, Celeste Lebbe, Barouyr Baroudjian, Tomohiro Enokida, Makoto Tahara, Max Schlaak, Kinan Hayani, Paul J. Broeckelmann, Friedegund Meier, Lydia Reinhardt, Philip Friedlander, Thomas Eigentler, Katharina C. Kaehler, Carola Berking, Lisa Zimmer, Lucie Heinzerling
Summary: Hematological immune-related adverse events (hem-irAE) are rare but severe complications of immune checkpoint inhibitors (ICI) therapy, including thrombocytopenia and leukopenia, which can lead to persistent changes or even fatal outcomes. Treatment may require second-line immunosuppression in addition to discontinuation of ICI and corticosteroids.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Immunology
Ting Cao, Xuyang Zhou, Xingbiao Wu, Ying Zou
Summary: The development of immune checkpoint inhibitors (ICIs) has significantly changed the treatment landscape for multiple malignancies. However, ICIs can also lead to immune-related adverse events (irAEs), especially affecting the skin. This review explores the immunological mechanisms and potential biomarkers for predicting cutaneous irAEs using multi-omics approaches. Additionally, the prognostic significance of cutaneous irAEs in immune checkpoint blockade therapy is discussed.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Blair S. Allais, Christopher J. Fay, Daniel Y. Kim, Yevgeniy R. Semenov, Nicole R. LeBoeuf
Summary: Decoupling toxicity from therapeutic effect is crucial in the field of cutaneous immune-related adverse events to immune checkpoint inhibitor therapy. Understanding the drivers of toxicity, tumor response, and resistance through population-level studies, cohort data, and cellular-level data is key. Increasing diagnostic specificity with consensus disease definitions has the potential to improve clinical care and research.
IMMUNOLOGICAL REVIEWS
(2023)
Article
Immunology
Shi-Tao Jiang, Yao-Ge Liu, Lei Zhang, Xin-Ting Sang, Yi-Yao Xu, Xin Lu
Summary: This study conducted a bibliometric analysis of immune-related adverse events (irAEs) research to map the basic knowledge structure including countries, institutions, authors, journals, and publications. The results showed that the United States, Japan, and China had the highest number of publications in this field, and immune checkpoint inhibitors, immunotherapy, and nivolumab were the most frequently used keywords.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Qinan Yin, Liuyun Wu, Lizhu Han, Xingyue Zheng, Rongsheng Tong, Lian Li, Lan Bai, Yuan Bian
Summary: Since the development of the first Immune Checkpoint Inhibitor, tumor immunotherapy has advanced significantly, leading to improved response rate and survival rate in many cancers. However, resistance and immune-related adverse events remain as challenges in achieving lasting response. This article summarizes the mechanisms of immune checkpoint inhibitors, different types of immune-related adverse events, and provides strategies and targets for prevention and therapeutic interventions.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Leah L. Thompson, Jordan T. Said, Edward B. Li, Jaewon Yoon, Nira A. Krasnow, Gabriel E. Molina, Nicole J. Polyakov, Ruth K. Foreman, Nicole R. LeBoeuf, Steven T. Chen
Summary: Evaluation of dermatologists' diagnostic accuracy for cutaneous immune-related adverse events from immune checkpoint inhibitors showed that experienced supportive oncodermatologists may benefit patient care through increased diagnostic accuracy, emphasizing the importance of integrating skin biopsy and oncodermatology referral in supportive cancer care.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Dermatology
A. Gault, A. E. Anderson, R. Plummer, C. Stewart, A. G. Pratt, N. Rajan
Summary: Checkpoint inhibitors have greatly improved outcomes in metastatic malignant melanoma, but can lead to cutaneous immune-related adverse effects. Anti-CTLA4 therapy has a higher rate of these adverse effects compared to anti-PD1/PDL1 therapies, which are usually managed supportively in mild cases. Delayed presentations of these adverse effects can make them difficult to distinguish from other dermatological conditions, and the identification of predictive biomarkers to manage severe adverse effects remains a challenge.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Anusuya Kawsar, Charlotte Edwards, Pooja Patel, Richard M. Heywood, Aakriti Gupta, Jasmine Mann, Christopher Harland, Kara Heelan, James Larkin, Paul Lorigan, Catherine A. Harwood, Rubeta N. Matin, Louise Fearfield
Summary: This multicentre observational study investigates the incidence and characteristics of bullous cutaneous immune-related adverse events (irAEs) associated with checkpoint inhibitor (CPI) therapy. The study finds that these irAEs are rare but can occur after cessation of treatment, and discontinuation of CPIs may be necessary for management. Prompt recognition and referral to dermatology are crucial for optimal management and patient outcomes.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Letter
Dermatology
Leah L. Thompson, Jaewon Yoon, Nira A. Krasnow, Michael S. Chang, Edward B. Li, Devon E. McMahon, Steven T. Chen
Summary: This cohort study examines the relationship between systemic corticosteroid exposure and infectious complications and survival outcomes in patients with cutaneous immune-related adverse events.
Article
Dermatology
Henry T. Quach, Douglas B. Johnson, Nicole R. LeBoeuf, Jeffrey P. Zwerner, Anna K. Dewan
Summary: ICIs can lead to a variety of cutaneous adverse events, ranging from common eczematous and morbilliform dermatoses to less common psoriasiform dermatoses and bullous disorders. The immunologic mechanism of ICIs may also cause rheumatologic adverse reactions with cutaneous manifestations, which can typically be managed with steroids. As ICIs become more widely prescribed, dermatologists will play a crucial role in accurately diagnosing and treating these toxicities to ensure favorable outcomes for patients.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Review
Food Science & Technology
Luigi Barrea, Matteo Megna, Sara Cacciapuoti, Evelyn Frias-Toral, Gabriella Fabbrocini, Silvia Savastano, Annamaria Colao, Giovanna Muscogiuri
Summary: Psoriasis is a chronic immune-mediated skin disease influenced by genetic and lifestyle factors. Nutrition and obesity are significant contributors to its pathogenesis and severity. Certain diets with anti-inflammatory properties, such as the very-low-calorie ketogenic diet (VLCKD), may improve clinical severity by reducing weight and systemic inflammation.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
(2022)
Letter
Dermatology
Alessia Villani, Gabriella Fabbrocini, Massimiliano Scalvenzi
DERMATOLOGIC THERAPY
(2022)
Letter
Dermatology
Lucia Genco, Teresa Battista, Matteo Noto, Mario De Lucia, Eleonora Cinelli, Massimiliano Scalvenzi, Gabriella Fabbrocini, Matteo Megna
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Delia Colombo, Luca Bianchi, Gabriella Fabbrocini, Salvatore Corrao, Annamaria Offidani, Luca Stingeni, Antonio Costanzo, Giovanni Pellacani, Ketty Peris, Federico Bardazzi, Giuseppe Argenziano, Silvana Ruffolo, Paolo Dapavo, Carlo Carrera, Maria Concetta Fargnoli, Aurora Parodi, Marco Romanelli, Piergiorgio Malagoli, Marina Talamonti, Matteo Megna, Massimo Raspanti, Matteo Paolinelli, Katharina Hansel, Alessandra Narcisi, Andrea Conti, Clara De Simone, Marco Adriano Chessa, Alina De Rosa, Eugenio Provenzano, Michela Ortoncelli, Chiara Moltrasio, Rosaria Fidanza, Martina Burlando, Annalisa Tonini, Francesca Maria Gaiani, Lucia Simoni, Alessandra Ori, Martina Fiocchi, Emanuela Zagni
Summary: The study aimed to provide real-world evidence of the effectiveness of biologics in Italian patients with moderate-severe psoriasis. Results showed that biologics were effective and well tolerated in psoriasis patients, with a high percentage of patients achieving PASI 75 at 16-52 weeks of treatment and a high sustained response rate after 1 year.
DERMATOLOGIC THERAPY
(2022)
Letter
Dermatology
Maddalena Napolitano, Mariateresa Nocerino, Vincenzo Picone, Fabrizio Martora, Gabriella Fabbrocini, Stefano Dastoli, Cataldo Patruno
DERMATOLOGIC THERAPY
(2022)
Letter
Dermatology
Fabrizio Martora, Gabriella Fabbrocini, Claudio Marasca
DERMATOLOGIC THERAPY
(2022)
Editorial Material
Pharmacology & Pharmacy
Maddalena Napolitano, Luca Potestio, Mario De Lucia, Mariateresa Nocerino, Gabriella Fabbrocini, Cataldo Patruno
Summary: Alitretinoin can be considered as a valid therapeutic option for patients with Chronic Hand Eczema who do not respond to conventional treatments. Clinical trials and real-life experiences have shown that it effectively improves both objective and subjective clinical symptoms, leading to a significant enhancement in patients' Quality of Life. Prior caution should be exercised in patients with certain chronic diseases or women of childbearing age when prescribing alitretinoin.
EXPERT OPINION ON PHARMACOTHERAPY
(2022)
Letter
Virology
Fabrizio Martora, Vincenzo Picone, Luigi Fornaro, Gabriella Fabbrocini, Claudio Marasca
JOURNAL OF MEDICAL VIROLOGY
(2022)
Letter
Dermatology
Alessia Villani, Gabriella Fabbrocini, Claudia Costa, Massimiliano Scalvenzi
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Dermatology
Z. Apalla, V Nikolaou, D. Fattore, G. Fabbrocini, A. Freites-Martinez, P. Sollena, M. Lacouture, L. Kraehenbuehl, A. Stratigos, K. Peris, E. Lazaridou, B. Richert, E. Vigarios, J. Riganti, B. Baroudjian, A. Filoni, R. Dodiuk-Gad, C. Lebbe, V Sibaud
Summary: The introduction of ICIs revolutionized oncologic therapy but also brought the risk of irAEs, with dermatologic irAEs being common. The EADV task force provided treatment recommendations for skin toxicities, focusing on balancing symptom relief with ongoing oncologic treatment.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Medicine, General & Internal
Claudio Marasca, Maria Carmela Annunziata, Elisa Camela, Adriana Di Guida, Luigi Fornaro, Matteo Megna, Maddalena Napolitano, Cataldo Patruno, Luca Potestio, Gabriella Fabbrocini
Summary: Inflammatory skin diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, and acne, have a significant impact on quality of life. The introduction of novel therapies has shown positive effects on the management of these diseases. Teledermatology has improved access to specialized dermatology care for patients in remote areas and saved costs.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Dermatology
Vasiliki A. Nikolaou, Zoe Apalla, Cristina Carrera, Davide Fattore, Pietro Sollena, Julia Riganti, Sonia Segura, Azael Freites-Martinez, Konstantinos Lallas, Maria Concetta Romano, Chrysa Oikonomou, Michela Starace, Meletios A. Dimopoulos, Athanassios Kyrgidis, Elizabeth Lazaridou, Priscila Giavedoni, Maria Carmela Annunziata, Ketty Peris, Maria Echeverria, Emilio Lopez-Tujillo, Konstandinos Syrigos, Chryssoula Papageorgiou, Sebastian Podlipnik, Gabriella Fabbrocini, Ana C. Torre, Christina Kemanetzi, Lorena Villa-Crespo, Aimilios Lallas, Alexander J. Stratigos, Vincent Sibaud
Summary: The study demonstrates that ICI-related skin toxicities do not share a single pattern and may depend on several factors, including the specific drug administered and the underlying malignancy. Patients with macular rash, vitiligo, or multiple skin toxicities were more frequently treated with ICIs for melanoma rather than non-small cell lung cancer. The combination of ICI and chemotherapy compared to ICI monotherapy was associated with a lower incidence of psoriatic rash, lichenoid, and eczematous reactions in patients, compared to those with pruritic rash.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Review
Pharmacology & Pharmacy
Alessia Villani, Francesca Nastro, Francesca Di Vico, Gabriella Fabbrocini, Maria Carmela Annunziata, Lucia Genco
Summary: This study provides a comprehensive overview of the efficacy, safety, and tolerability of oral isotretinoin in the treatment of acne. It also emphasizes the importance of personalized treatment protocols based on the severity and type of acne lesions.
EXPERT OPINION ON DRUG SAFETY
(2022)
Article
Dermatology
Rohan Mital, Tracey S. Otto, Andrei Savu, Emily Baumrin, Adela R. Cardones, Marta Carlesimo, Gemma Caro, Azael Freites-Martinez, Jesse P. Hirner, Alina Markova, Beth N. McLellan, Alfredo Rossi, Maxwell B. Sauder, Lucia Seminario-Vidal, Vincent Sibaud, Dwight H. Owen, Brittany O. Dulmage, Steven T. Chen, Benjamin H. Kaffenberger
Summary: Cutaneous immune-related adverse events (cirAEs) are common side effects of immune checkpoint inhibitor (ICI) therapy, and current treatment algorithms are still poorly defined. This study collected data from a multi-institutional registry and identified various treatment options, achieving positive outcomes in patients. Evaluation: 8 out of 10.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2023)
Article
Oncology
Pietro Sollena, Nikolaou Vasiliki, Elias J. Kotteas, Alexander J. Stratigos, Davide Fattore, Armando Orlandi, Maria Mannino, Marcello Di Pumpo, Monika Fida, Michela Starace, Zoe Apalla, Maria Concetta Romano, Julia Riganti, Sonia Segura, Azael Freites Martinez, Gabriella Fabbrocini, Vincent Sibaud, Ketty Peris
Summary: Treatment with CDK4/6 inhibitor in combination with endocrine therapies can improve progression-free survival in patients with hormone receptor-positive, HER2-negative, advanced breast cancer. However, limited data exists on its cutaneous adverse events. This retrospective study investigated the prevalence, types, and management of cutaneous adverse events during CDK4/6 inhibitor treatment.